{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.16","upperLimit":"26.26","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT\n\n* CT scans of chest, abdomen and pelvis for TNM stage IV patients who had positive findings prior to treatment.\n* CBC with Sézary cell count and/or flow cytometry in patients with Sézary syndrome.\n* Dermatologic responses will be determined by the Severity-Weighted Assessment Tool (SWAT), a standardized approach to measuring the extent and severity of overall skin disease in patients with CTCL Primary skin tumor assessments were made by the modified Severity-Weighted Assessment Tool (mSWAT) \\[12, 13\\]; the Composite Assessment of Index Lesion Severity (CA) \\[9, 14\\] was used a secondary scale. Progression was defined as ≥25% increase in mSWAT skin score and ≥50% increase in the sum of the products of the greatest diameters of involved lymph nodes over baseline for patients with involved lymph nodes with stage IV disease","dispersionType":"Full Range","groups":[{"description":"Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.","id":"OG000","title":"Doxil and Targretin® (Bexarotene)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 years","title":"Median Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}